Article
Introduction of a glycosylation site in the constant region decreases the aggregation of adalimumab Fab.
Biochemical and biophysical research communications - 5 Sept 2018
Nakamura Hitomi, Oda-Ueda Naoko, Ueda Tadashi, Ohkuri Takatoshi
Abstract excerpt
The production of therapeutic monoclonal antibodies is costly; therefore, antigen-binding fragments (Fabs) can be used instead. However, their tendency toward aggregation can reduce the half-life in the plasma and the therapeutic effectiveness. To examine the effect of glycosylation on the properties of the Fab of a therapeutic antibody, an N-glycosylation site was introduced at position 178 of the H-chain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.